Page last updated: 2024-09-02

tadalafil and roflumilast

tadalafil has been researched along with roflumilast in 8 studies

Compound Research Comparison

Studies
(tadalafil)
Trials
(tadalafil)
Recent Studies (post-2010)
(tadalafil)
Studies
(roflumilast)
Trials
(roflumilast)
Recent Studies (post-2010) (roflumilast)
1,7423921,08956690425

Protein Interaction Comparison

ProteinTaxonomytadalafil (IC50)roflumilast (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0008
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0008
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0008
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0058
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0008
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)0.0008
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)0.0005
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)0.0003
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)0.025
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)0.0475
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)0.0008
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)0.001
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)0.0008
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)0.0008
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)0.0008

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's3 (37.50)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY1
Hughes, RA; Manallack, DT; Thompson, PE1
Huang, YY; Li, Z; Luo, HB; Wu, D; Wu, Y1
Chai, S; Chen, S; Deng, L; Du, K; Shen, R; Sun, H; Sun, T; Xi, M; Xie, M1
Kertys, M; Kosutova, P; Medvedova, I; Mikolka, P; Mokra, D; Mokry, J; Urbanova, A1
Kertys, M; Mokry, J; Urbanova, A1
Akhtar, M; Hasan, N; Najmi, AK; Parvez, S; Yar, MS; Zameer, S1
Agis-Torres, Á; Barahona, MV; Benedito, S; Climent, B; Fernandes, VS; Hernández, M; López-Oliva, ME; Martínez, MP; Navarro-Dorado, J; Prieto, D; Recio, P1

Reviews

3 review(s) available for tadalafil and roflumilast

ArticleYear
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
    Journal of medicinal chemistry, 2005, May-19, Volume: 48, Issue:10

    Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines

2005
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Journal of medicinal chemistry, 2018, 07-12, Volume: 61, Issue:13

    Topics: Alzheimer Disease; Animals; Cognition; Humans; Phosphodiesterase Inhibitors

2018
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
    European journal of medicinal chemistry, 2022, Mar-15, Volume: 232

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Animals; Cognition; Cyclic GMP; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases

2022

Other Studies

5 other study(ies) available for tadalafil and roflumilast

ArticleYear
Structural basis for the activity of drugs that inhibit phosphodiesterases.
    Structure (London, England : 1993), 2004, Volume: 12, Issue:12

    Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary

2004
Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2017, Volume: 68, Issue:5

    Topics: Aminopyridines; Animals; Benzamides; Biomarkers; Cyclopropanes; Guinea Pigs; Inflammation Mediators; Lung; Male; Organ Culture Techniques; Ovalbumin; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Random Allocation; Respiratory Hypersensitivity; Tadalafil; Treatment Outcome

2017
Determination of Phosphodiesterase Inhibitors Tadalafil, Roflumilast and Roflumilast N-Oxide Using LC-MS in Guinea Pig Plasma.
    Journal of chromatographic science, 2018, Nov-01, Volume: 56, Issue:10

    Topics: Aminopyridines; Animals; Benzamides; Chromatography, High Pressure Liquid; Cyclopropanes; Guinea Pigs; Linear Models; Male; Phosphodiesterase Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Tadalafil; Tandem Mass Spectrometry

2018
Roflumilast and tadalafil improve learning and memory deficits in intracerebroventricular Aβ1-42 rat model of Alzheimer's disease through modulations of hippocampal cAMP/cGMP/BDNF signaling pathway.
    Pharmacological reports : PR, 2021, Volume: 73, Issue:5

    Topics: Alzheimer Disease; Aminopyridines; Amyloid beta-Peptides; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic GMP; Cyclopropanes; Cytokines; Gene Expression Regulation; Hippocampus; Male; Memory Disorders; Morris Water Maze Test; Oxidative Stress; Peptide Fragments; Random Allocation; Rats; Rats, Wistar; Tadalafil; Vasodilator Agents

2021
In vitro inhibition of phosphodiesterase type 4 enhances rat corpus cavernosum nerve-mediated relaxation induced by gasotransmitters.
    Life sciences, 2022, May-01, Volume: 296

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aminopyridines; Animals; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Dose-Response Relationship, Drug; Gasotransmitters; Hydrogen Sulfide; Male; Muscle Relaxation; Nitroarginine; Penis; Peripheral Nerves; Rats, Wistar; Tadalafil

2022